Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,418 active trials60 approved drugs271 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,888 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,375)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04893538 | Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma | unknown | — | 100 | Latakia UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02313389 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma(BLOCAGE-01) | unknown | Phase 3 | 428 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 2, 2022 |
| clinicaltrials |
| NCT05155839 | Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) | unknown | Phase 1 | 108 | Shanghai Miracogen Inc.INDUSTRY | 1 | Feb 22, 2022 | clinicaltrials |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT04253496 | Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)(LOC-MODEL) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05238064 | Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Feb 14, 2022 | clinicaltrials |
| NCT05236621 | A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 85 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 11, 2022 | clinicaltrials |
| NCT04273425 | Bone Pain in Multiple Myeloma- a Translational Study(BPMM) | unknown | — | 35 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT02575144 | GEM-CLARIDEX: Ld vs BiRd(GEM-CLARIDEX) | unknown | Phase 3 | 286 | PETHEMA FoundationOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT03571997 | Study of Prognostic Factors in Adult Lymphoblastic Lymphoma | unknown | — | 30 | PETHEMA FoundationOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05052970 | Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM | unknown | Phase 1 | 60 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 1 | Feb 1, 2022 | clinicaltrials |
| NCT03837873 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | unknown | Phase 2 | 118 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05206045 | Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies(SURPASSe) | unknown | — | 700 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05206071 | Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma | unknown | N/A | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05203809 | Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies(THERMAL) | unknown | — | 20 | Malaghan Institute of Medical ResearchOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT03574454 | Machine Learning in Myeloma Response(MALIMAR) | unknown | N/A | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05184595 | Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib(ADHOMY2) | unknown | N/A | 52 | Central Hospital, Nancy, FranceOTHER | 0 | Jan 11, 2022 | clinicaltrials |
| NCT05179213 | Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05167630 | Prognosis Factors in Patients With Primary Central Nervous System Lymphoma | unknown | — | 40 | Zhengzhou UniversityOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT05164770 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 160 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05137886 | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | unknown | Phase 2 | 47 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05155215 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 68 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05149170 | Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05143112 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05008536 | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 27 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05097443 | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 130 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05127135 | Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies | unknown | Phase 1 | 30 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT04818372 | Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | unknown | Phase 1 | 87 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Nov 12, 2021 | clinicaltrials |
| NCT05076097 | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma | unknown | Phase 2 | 29 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05114109 | Isatuximab in Type I Cryoglobulinemia(ICE) | unknown | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT04287660 | Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | unknown | Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05088330 | A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM | unknown | N/A | 76 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Oct 21, 2021 | clinicaltrials |
| NCT03505944 | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma(VALERIA) | unknown | Phase 1 / Phase 2 | 59 | Nordic Lymphoma GroupNETWORK | 4 | Oct 13, 2021 | clinicaltrials |
| NCT04320420 | Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²)(APA²) | unknown | N/A | 57 | WepromOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT05024357 | A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL | unknown | N/A | 80 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05026229 | A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05059847 | Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia Adults | unknown | N/A | 114 | Hospital General de MexicoOTHER_GOV | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05059912 | CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03439501 | Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | unknown | Phase 2 | 21 | Samsung Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT04617704 | BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05049473 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | unknown | Phase 2 | 100 | PETHEMA FoundationOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT05047107 | Biology and Genetics of Smouldering Myeloma(COSMOS) | unknown | — | 500 | University College, LondonOTHER | 1 | Sep 16, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Mar 3, 2022source: clinicaltrials